As previously reported, simultaneous blocking of innate (CD47) and adaptive (PD-L1) checkpoints on tumor cells limits immune evasion and boosts anti-PD-L1 response 70, 71, suggesting that harnessing the innate immune system is a promising strategy to prolong survival outcomes of patients treated with ICB immunotherapy. The gene discussed is CD274; the disease is neoplasm.